Navigation Links
Frost & Sullivan Identifies Proscia as a Game-changing Company in Cloud-based Digital Pathology

Proscia Inc., a software solutions provider for digital pathology, announced today that Frost & Sullivan, the Growth Partnership Company, had named Proscia as the recipient of its 2017 Best Practices in Enabling Technology Leadership Award in Digital Pathology. Frost & Sullivan and its global team of analysts and consultants independently evaluated companies servicing the digital pathology industry by two key factors—technology leverage and customer impact—and identified Proscia as a company that continually invests in new technologies that meet this criteria.

“To achieve enabling technology leadership is never an easy task, but it is one made even more difficult considering today’s competitive intensity, customer volatility, and economic uncertainty—not to mention the difficulty of innovating in an environment of escalating challenges to intellectual property,” said David Frigstad, Chairman, Frost & Sullivan. “Within this context, naming Proscia as the recipient of this award signifies an even greater accomplishment in the field of digital pathology and we recognize Proscia as a futuristic, disruptive, and game-changing company to watch in this industry.”

“Pathology laboratories have been transitioning to digital workflows over the past 8 to 10 years, added Divyaa Ravishankar, Industry Principal and Associate Fellow, Frost & Sullivan. “As the traditional pathology workflow gradually moves towards modernization, labs will see adoption of faster imaging and next generation analytical tools, such as Proscia’s, designed to support digital processes.”

Proscia’s digital pathology software is aimed at augmenting the work of the pathologist through the development of a platform that allows for more efficient data management, telepathology, and image analysis. Currently, there are over 800 users of Proscia’s cloud-based technology for digital pathology across 125 institutions with a considerable number of slides under management across 40 countries.

“Proscia is honored to have earned Frost & Sullivan’s recognition for its strategic thought leadership, innovation, and performance exhibited in the cloud pathology space,” said David West, Jr., CEO, Proscia. “With the objective of advancing cancer care and treatment, Proscia is well positioned to usher in computational pathology by bringing together machine learning and cloud computing to revolutionize how histological patterns are read on whole slide images.”

Frost & Sullivan continuously conducts research of a wide range of markets across multiple sectors and geographies. As part of this ongoing research, it identifies companies that continually invest in new technologies to deliver a unique and superior customer experience, or invest in technologies that enhance a vast array of applications. In order for a company to qualify for the Best Practices in Enabling Technology Leadership Award, it must be best-in-class in three key areas: understanding demand, nurturing the brand, and differentiating from the competition. A full description of the award and its criteria can be found here.

About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best-in-class positions in growth, innovation, and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best practice models to drive the generation, evaluation, and implementation of powerful growth strategies. Frost & Sullivan leverages more than 50 years of experience in partnering with Global 1000 companies, emerging businesses, and the investment community from 45 offices on 6 continents. To join our Growth Partnership, please visit

About Proscia
Proscia was founded in 2014 by a team out of Johns Hopkins, the Moffitt Cancer Center, and the University of Pittsburgh to improve clinical outcomes and accelerate the discovery of breakthrough advancements in the fight against cancer. Using modern computing technologies that unlock hidden data not visible to the human eye and turning that data into valuable insights in the fight against cancer, the company is dedicated to improving the efficiency, speed, and quality of pathology diagnostics and research. To learn more, please visit

Read the full story at

Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved

Related biology technology :

1. University of Miami Announces Creation of the Frost Institutes for Science and Engineering
2. APACs Volume Share and Margins in the Contract Research Organisation Market Set to Increase, Finds Frost & Sullivan
3. Acura Earns Accolades from Frost & Sullivan for Developing a Novel Technology Platform to Prevent the Abuse of Opioid-based Medication through Oral Administration
4. Stem Cell Therapy to Redefine Regenerative Medicine, says Frost & Sullivan
5. Developing Nations Emerge as the Building Blocks of the Asia-Pacific Amino Acids and Specialty Proteins Market, says Frost & Sullivan
6. Embrace the Future of Medical Technologies with Frost & Sullivan
7. Bioadhesives Poised to Replace Synthetic Solutions, Finds Frost & Sullivan
8. Frost & Sullivan Awards CyVek, Inc. the 2014 North American Immunoassay Technology Innovation Leadership Award
9. Frost & Sullivan Recognizes DSM Biomedicals Outstanding Growth as a Total Solutions Provider in the Medical Device Coatings Market
10. Frost & Sullivan: 4-D Printing to Usher in Age of Low-Labor, Fast-Paced Product Manufacturing
11. Biocompatible Protective Coatings Widen Application Scope in Medical Devices, Finds Frost & Sullivan
Post Your Comments:
(Date:5/21/2020)... ... May 20, 2020 , ... Exo (pronounced “Echo”) ... the company’s executive vice president of product engineering and report directly to CEO ... imaging space, bringing more than 24 years of technology leadership experience from Google, ...
(Date:5/15/2020)... , ... May 15, 2020 , ... Sentien Biotechnologies, Inc., ... of Richard Ganz as Executive Chairman. Mr. Ganz will continue to lead Sentien’s ... well as work closely with CEO Brian Miller and Sentien’s management team. ...
(Date:5/14/2020)... ... May 13, 2020 , ... Early stages of ... little or no information on the drug’s mechanism of action (MOA). Gene expression ... by measuring the activity of molecular pathways. This information can complement phenotypic readouts ...
(Date:5/5/2020)... ... May 05, 2020 , ... ... the launch of its iGlucose® LTE Cat-M Cellular Connected Diabetes Blood ... Cat-M1 technology, the industry’s newest and broadest cellular connectivity available, to provide patients ...
Breaking Biology Technology:
(Date:4/22/2020)... ... April 20, 2020 , ... RCH Solutions (RCH ... of all sizes, announces the hiring of Michael Wlodarczyk as Director of Sales and ... to support and grow the company’s already strong presence across the Northeast. , “We ...
(Date:4/18/2020)... CAMBRIDGE, Mass. (PRWEB) , ... April 16, 2020 , ... ... for gene and cell therapy, today announced it will present a company update on ... 2020 Virtual Investor Summit taking place on April 22 and 23. Dieter Lingelbach, ...
(Date:4/15/2020)... ... April 15, 2020 , ... NDA Partners Chairman Carl Peck, ... former Senior Science Policy Advisor with the Center for Drug Evaluation and Research and ... and Radiological Health, has joined the firm as an Expert Consultant. , Dr. Suleiman ...
Breaking Biology News(10 mins):